The U.S. Food and Drug Administration (FDA) has selected Dexcom as the first company to participate in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program, marking a significant development in the agency’s approach toward evaluating digital health technologies for chronic disease management. The Dexcom TEMPO pilot will examine how continuous glucose monitoring technology combined with digital health insights can support earlier intervention, improve disease management, and generate real-world evidence for healthcare decision-making.
The selection places Dexcom at the forefront of a new regulatory pathway focused on understanding how digital health solutions perform outside traditional clinical trial environments. As healthcare systems worldwide continue to face rising challenges associated with chronic diseases, regulators and healthcare providers are increasingly exploring technology-driven approaches that enable earlier diagnosis, continuous monitoring, and personalized treatment strategies.
Through the Dexcom TEMPO pilot, the company will evaluate an AI-supported glucose health program that integrates data from its Dexcom G7 and Stelo continuous glucose monitoring platforms with additional health information, including nutrition, physical activity, sleep patterns, and stress-related factors. The objective is to provide healthcare professionals and eligible users with deeper insights into metabolic health while assessing how digital interventions can contribute to improved outcomes among individuals at risk of prediabetes and Type 2 diabetes.
The initiative also reflects the growing importance of real-world evidence in healthcare regulation. Traditionally, medical technologies designed for disease management require extensive regulatory review before receiving authorization for clinical use. However, the rapid growth of connected medical devices, wearable technologies, and software-based healthcare solutions has created a need for regulatory frameworks that can evaluate innovation while maintaining patient safety standards.
FDA’s TEMPO Program Signals Shift Toward Data-Driven Chronic Disease Management
The Dexcom TEMPO pilot is part of the FDA’s broader effort to establish a more flexible framework for evaluating digital health technologies. The program operates alongside the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model, which aims to support technology-enabled approaches for managing major chronic conditions, including diabetes, hypertension, chronic kidney disease, obesity, depression, and anxiety.
The ACCESS Model focuses on creating sustainable healthcare delivery models where digital tools can demonstrate measurable improvements in patient outcomes. Under the TEMPO initiative, the FDA will collect additional information on how digital health technologies perform in real-world settings and how these solutions can complement traditional healthcare services.
The FDA’s decision to begin the program with Dexcom highlights the increasing role of continuous glucose monitoring technologies in preventive healthcare. Diabetes management has traditionally relied on periodic glucose measurements, but CGM systems have transformed disease monitoring by enabling continuous tracking of glucose fluctuations and providing patients and physicians with more comprehensive health information.
Dexcom has emerged as one of the leading companies in the global CGM sector, with its technology increasingly being used beyond diabetes treatment toward broader metabolic health monitoring. The company’s expansion into preventive care reflects a larger healthcare industry trend where wearable devices and digital platforms are becoming tools for identifying health risks before conditions become more severe.
The Dexcom TEMPO pilot will allow the company to generate additional evidence regarding how glucose biosensing technology combined with digital health programs can influence patient behavior, improve health awareness, and support earlier intervention strategies.
Digital Health Companies Increasingly Focus on Real-World Outcomes and Healthcare Integration
The launch of the Dexcom TEMPO pilot comes at a time when healthcare organizations are placing greater emphasis on outcome-based care models. As chronic diseases continue to create significant financial and operational pressure on healthcare systems, digital health technologies are being evaluated not only for their innovation but also for their ability to deliver measurable improvements in patient care.
For companies developing digital healthcare solutions, regulatory recognition and evidence generation are becoming increasingly important factors influencing adoption. Healthcare providers and payers are demanding stronger proof that digital tools can improve clinical outcomes, reduce healthcare costs, and enhance patient engagement.
Dexcom’s participation in the FDA pilot could strengthen the company’s position in the expanding digital health ecosystem by providing additional evidence supporting the role of CGM technology in preventive healthcare. The company has stated that findings from the program could contribute to future research involving broader cardiometabolic health applications.
Meanwhile, artificial intelligence adoption in healthcare continues to expand across other areas of clinical operations. Ardent Health recently announced that its ambient AI platform from Ambience Healthcare surpassed one million patient encounters, demonstrating the increasing adoption of technology designed to reduce administrative workload for clinicians.
The platform is currently used in a significant majority of ambulatory visits across Ardent-affiliated healthcare facilities, helping physicians reduce documentation time and focus more attention on patient interactions. According to the healthcare provider, clinicians using the technology save more than three hours per week on documentation-related activities.
These developments indicate that healthcare technology adoption is moving beyond experimental stages toward practical integration within everyday clinical workflows. From glucose monitoring and chronic disease management to physician documentation and operational efficiency, healthcare organizations are increasingly using digital tools to address long-standing challenges.
The Dexcom TEMPO pilot represents an important milestone in this transition. By combining continuous health monitoring, digital insights, and regulatory evaluation, the initiative could help shape future approaches for managing chronic diseases through technology-enabled care models.
As the FDA continues selecting additional participants for the TEMPO program, the healthcare industry will closely monitor how these initiatives influence regulatory pathways, reimbursement models, and the future adoption of digital health solutions across clinical settings.
